PROTAC CDK2/9 Degrader-1
PROTAC CDK2/9 Degrader-1 (Compound F3) 是 CDK2 (DC50=62 nM) 和 CDK9 (DC50=33 nM) 的有效双降解剂。PROTAC CDK2/9 Degrader-1 通过有效阻断前列腺癌 PC-3 细胞S期和 G2/M 期的细胞周期，抑制前列腺癌 PC-3 细胞增殖 (IC50=0.12 µM)。PROTAC CDK2/9 Degrader-1 是一种 CDK 抑制剂与 CRBN 配体结合的 PROTAC。
此产品仅用于科学研究，我们不为任何个人用途提供产品和服务
-
包装价格促销价数量
-
5mg￥8100.006480.00- +
-
10mg￥13350.0010680.00- +
-
25mg￥26175.0020940.00- +
-
50mg￥40075.0032060.00- +
- 货号: ajcx34176
- CAS: 2408641-24-5
- 别名:
- 分子式: C40H41N13O7
- 分子量: 815.84
- 纯度: ＞98%
- 溶解度: DMSO : 130 mg/mL (159.34 mM; Need ultrasonic)
- 储存: Store at -20°C
- 库存: 现货
Background
PROTAC CDK2/9 Degrader-1 (Compound F3) is a potent dual degrader for CDK2 (DC50=62 nM) and CDK9 (DC50=33 nM). PROTAC CDK2/9 Degrader-1 suppresses prostate cancer PC-3 cell proliferation (IC50=0.12 µM) by effectively blocking the cell cycle in S and G2/M phases. PROTAC CDK2/9 Degrader-1 is a PROTAC by tethering CDK inhibitor with CRBN ligand[1].
PROTAC CDK2/9 Degrader-1 (0.25-3 μM; 48 hours) induces cell cycle blockage at the G2/M phase[1].PROTAC CDK2/9 Degrader-1 (500 nM; 2-24 hours) down-regulates the Mcl-1 protein level in PC-3 cells[1].PROTAC CDK2/9 Degrader-1 effectively degrades CDK2/9 in cell lines MCF-7, HCT-116 and 22Rv1, which all have high CDK2/9 expression[1].PROTAC CDK2/9 Degrader-1 inhibits both CDK2 and CDK9, with IC50 as 7.42 nM and 14.50 nM, respectively[1].
[1]. Zhou F, et al. Development of selective mono or dual PROTAC degrader probe of CDK isoforms. Eur J Med Chem. 2019 Dec 6;187:111952.
